Chelsea receives record Premier League fine for breaches of financial rules Chelsea are fined a record total of $20.2 million for historical breaches of the Premier League's financial regulations, but avoid a points deduction.

Chelsea receives record Premier League fine for breaches of financial rules

#SportsGov #meso

Chelsea are fined a record total of $20.2 million for historical breaches of the Premier League's financial regulations, but avoid a points deduction.

Soccer Football
www.abc.net.au/news/2026-03...

Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of Teresa Montagut MD, PhD in the newly established position of Head of Clinical Development and Medical

#MESO Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

www.stocktitan.net/news/MESO/dr-teresa-mont...

Meso Brings AI‑Driven Curriculum Planning to Classrooms in Ireland and Beyond Meso, an education technology spin‑out from the ADAPT Centre for AI‑Driven Digital Content Technology at Trinity College Dublin, is starting a rollout of its AI‑powered curriculum planning platform…

#Meso an AI‑powered curriculum planning tool, from the #ADAPTCentre at #TrinityCollegeDublin, takes the heavy lifting out of curriculum planning so teachers can focus more on student learning. is available now for schools at home and abroad buff.ly/Rz57GI3
#AIinEducation #CurriculumPlanning

Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment Mesoblast (Nasdaq:MESO) reported real-world pediatric outcomes for Ryoncil (remestemcel-L-rknd) since commercial launch in March 2025. Of the first 25 children treated post-launch, 21 (84%) completed the FDA-label 28-day regimen and were alive; four patients who did not complete treatment died within 28 days. Mesoblast has onboarded 45 transplant centers toward a 64-center target covering 94% of U.S. transplants, and reports payer coverage for over 260 million U.S. lives. A CMS HCPCS J-Code issued Oct 1, 2025 increased CMS usage in the last quarter. A pivotal adult trial with BMT-CTN is expected to begin site enrollment this quarter to seek FDA label expansion.

#MESO Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment

www.stocktitan.net/news/MESO/real-world-com...

FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy Mesoblast (NASDAQ:MESO) reported FDA feedback after a Type B meeting on a potential BLA for rexlemestrocel-L in chronic discogenic low back pain (CLBP). FDA acknowledged that pain-intensity results from the MSB-DR003 Phase 3 trial favor rexlemestrocel-L versus placebo and confirmed a clinically meaningful 12-month pain reduction can support product efficacy. FDA also said robust opioid-reduction results from at least one adequate and well-controlled trial could be included in product labeling. A second Phase 3 study, MSB-DR004, is >50% enrolled across 40 U.S. sites and aims for a 300-patient enrollment target within about three months. Rexlemestrocel-L holds RMAT designation for CLBP.

#MESO FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy

www.stocktitan.net/news/MESO/fda-acknowledg...

Ryoncil® Sales Increase 60% in December Quarter to US$35.1M Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$35.1 million on Ryoncil

#MESO Ryoncil® Sales Increase 60% in December Quarter to US$35.1M

www.stocktitan.net/news/MESO/ryoncil-sales-...

Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines

#MESO Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line

www.stocktitan.net/news/MESO/mesoblast-reti...

Roštilj Barbecue 60cm s motorom 230V omogućuje ravnomjerno pečenje velikih komada mesa. Dupli grill, površina 56×30 cm, max opterećenje 8 kg. Naruči sada!
rasprodaja.eu/pr/rostilj-na-ugljen-bar...

#Roštilj #Barbecue #Roštiljanje #Vrt #Dom #Meso #Piletina

A new #education #tech spin-out, #MESO, from the @researchireland.ie ADAPT Centre at @tcddublin.bsky.social has secured €500,000 in Enterprise Ireland funding to bring its #AI-driven curriculum planning platform to schools across Ireland and abroad: www.adaptcentre.ie/news-and-eve...

This month's #ADAPTRadio podcast features Dr Chris Byrne, founder & CEO of #MESO; an #AI-powered, education technology spin-out from the @researchireland.ie ADAPT Centre and @tcddublin.bsky.social
Listen: www.adaptcentre.ie/podcasts/ada...
#TeacherPlanning #PersonalisedLearning #EdTechInnovation

Trade Alerts, Wednesday November 26, 2025 – Crystal Equity Research

Small-cap stocks gapping up in trading, Wed Nov 26th - #PW #BQ #WOOF #VRCA #TSSI #ONEW #MESO #KALA #DEFT #CTXR #AMBR - More: crystalequityresearch.com/trade-alerts... - #smallcap

Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue Mesoblast (Nasdaq: MESO) issued a trading update at its Annual General Meeting, reporting expected Ryoncil gross revenue of more than US$30.0 million for the quarter ending Dec 31, 2025. The company said this represents a >37% increase versus US$21.9 million in Ryoncil gross revenue for the prior quarter ended Sep 30, 2025. The AGM address included a comprehensive operational overview alongside the trading update.

#MESO Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue

www.stocktitan.net/news/MESO/mesoblast-trad...

Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids Mesoblast (Nasdaq: MESO) and the NIH-funded BMT CTN will launch a pivotal Phase 3 trial of Ryoncil (remestemcel-L-rknd) as part of a first-line regimen for adults with severe acute graft versus host disease refractory to corticosteroids (SR-aGvHD).The randomized trial will compare ruxolitinib alone versus ruxolitinib plus Ryoncil, with the protocol to be submitted to FDA and enrollment targeted to begin in Q1 2026. Background data cited include 44–58% non-response to ruxolitinib at Day 28 in supportive studies and 20–30% 100-day survival after ruxolitinib failure; Mesoblast reported 76% Day-100 survival in its Expanded Access program for patients ≥12 who failed ruxolitinib or other second-line agents.

#MESO Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids

www.stocktitan.net/news/MESO/mesoblast-and-...

Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation Mesoblast (Nasdaq: MESO) said the FDA scheduled a meeting in early December to discuss data from its first Phase 3 trial (MSB-DR003) of rexlemestrocel-L in chronic low back pain (CLBP), including opioid reduction and cessation outcomes.In the randomized 404-patient trial, 168 patients were on opioids at baseline and a single intra-discal injection of rexlemestrocel-L + HA produced >3-fold more patients who ceased all opioids by 36 months versus saline (p=0.008). Rexlemestrocel-L holds RMAT designation. Mesoblast is recruiting a 300-patient confirmatory Phase 3 across 40 US sites, with enrollment expected to complete in the coming quarter. The company is seeking FDA approval based on 12-month CLBP reduction data.

#MESO Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation

www.stocktitan.net/news/MESO/mesoblast-to-m...

Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent activities for the first

#MESO Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch

www.stocktitan.net/news/MESO/ryoncil-net-re...

Ryoncil® Revenues Increase 66% in Second Quarter Post Launch Mesoblast (Nasdaq: MESO) reported gross Ryoncil sales of US$21.9 million for the quarter ended September 30, 2025, a 66% increase versus the prior quarter ended June 30, 2025 with a similar gross-to-net adjustment.Ryoncil (remestemcel-L-rknd) is the first FDA-approved mesenchymal stromal cell product and the only product approved for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD). Management cited payer reimbursement progress and noted adoption is expected to accelerate following a permanent CMS J-Code effective October 1, 2025.

#MESO Ryoncil® Revenues Increase 66% in Second Quarter Post Launch

www.stocktitan.net/news/MESO/ryoncil-revenu...

From #Ferrara2025 to… #Faro2030! 🎉
We’re excited that #ICArEHB – Univ. Algarve will host the 12th International Conference on the #Mesolithic in Europe. For the 1st time, #MESO comes to Portugal 🇵🇹 Algarve awaits! ☀️

Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access Mesoblast (Nasdaq:MESO) announced that Medicare & Medicaid Services activated a permanent HCPCS J‑Code J3402 for Ryoncil (remestemcel‑L‑rknd) effective October 1, 2025. The J‑Code creates a standardized billing and reimbursement pathway for Ryoncil, intended to facilitate broader patient access and simplify payment for providers treating steroid‑refractory acute graft‑versus‑host disease (SR‑aGvHD) in children. The release notes Ryoncil is the first mesenchymal stromal cell product approved by the FDA and the only therapy approved for children under age 12 with SR‑aGvHD. Providers may submit claims using J3402 for dates of service on or after October 1, 2025, and are directed to ryoncil.com for coding guidance.

#MESO Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access

www.stocktitan.net/news/MESO/ryoncil-receiv...

MoonPay Acquires Meso in a Bid to Accelerate Global Payments Transformation - Crypto Economy MoonPay acquired Meso to strengthen its payments network, integrating banks, card, stablecoins, and blockchains under a unified framework.

💣 MoonPay acquires Meso to boost global payments 💳

MoonPay confirmed the acquisition of Meso, strengthening its strategy to expand and transform worldwide payment infrastructure.

#MoonPay #Meso #Payments #Crypto #Fintech

$50M Funding Option: Biotech Leader Mesoblast Secures Convertible Notes at 26% Premium to Market Mesoblast enters agreement for up to $50M in convertible notes with 5% coupon, convertible at $16.25 per ADR. Deal includes warrants and represents 126% premium to Nasdaq close.

#MESO Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes

www.stocktitan.net/news/MESO/mesoblast-ente...

Nasdaq Down Over 1%; Alibaba Shares Jump Following Q1 Results - Alibaba Gr Hldgs (NYSE:BABA), Ambarella (NASDAQ:AMBA)

Nasdaq Down Over 1%; Alibaba Shares Jump Following Q1 Results read more

#AMBA #BABA #Equities #IPDN #MESO #Mid #Day #Market #Update #MOVE #MRVL

Origin | Interest | Match

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil® Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update

#MESO Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®

www.stocktitan.net/news/MESO/banner-year-fo...

Cellular Medicine Leader Mesoblast to Present Full Year 2025 Results and Pipeline Updates Mesoblast (NASDAQ:MESO), leader in allogeneic cellular medicines, will discuss FY2025 financial results and operational highlights via webcast on August 28 at 6:30pm EDT.

#MESO Mesoblast Financial Results and Corporate Update Webcast

www.stocktitan.net/news/MESO/mesoblast-fina...

Roštilj Trapani – Mali, moćan i spreman za akciju! 🍖 Kompaktan, sklopiv, s kotačima i kromiranom rešetkom za savršeno pečenje gdje god poželiš! rasprodaja.eu/pr/rostilj-na-drveni-ugl...

#rostilj #trapani #ljeto #bbq #rostiljanje #terasa #vrt #meso #hrana #outdoor

In business and life, you will have macro (large) events and micro (small) events that will affect you, as well as meso (medium) in between. #macro #micro #meso #events #business #life #impact #affect

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#TLN, #BULL, #CRSP, #IVZ, #MESO

#OptionFlow #OptionsTrading #Trading

Successful Commercial Launch of Ryoncil® Mesoblast (NASDAQ:MESO) reported strong initial results from the commercial launch of Ryoncil®, its FDA-approved mesenchymal stromal cell product for steroid-refractory acute graft-versus-host disease in children. The company achieved $13.2 million in gross revenue from Ryoncil® sales in its first quarter post-launch (March 28 - June 30, 2025).Key operational highlights include: onboarding of 25+ transplant centers, coverage expansion to over 250 million US lives, and implementation of mandatory state CMS coverage effective July 1. The company maintains a strong cash position of $162 million and secured seven years of orphan-drug exclusivity plus biologic exclusivity through 2036.Additionally, Mesoblast is advancing its pipeline with ongoing developments in chronic heart failure and chronic low back pain treatments.

#MESO Successful Commercial Launch of Ryoncil®

www.stocktitan.net/news/MESO/successful-com...

Big ole dirty meso/tornado cyclone. It was raining saturated dirt after the tornado had sucked up tons of earth. Was rated ef4. #tornado #wedge #dirt #meso #wxsky